stockrow
Saturday 7 November 2026
Export NVCT’s income statement to Excel — free account
Nuvectis Pharma, Inc.
NVCT Healthcare Biotechnology
- EPS
- −131.9%
- Free cash flow
- −34.6%
Quarter to September 2026, against a year earlier
20.81
3.05
+17.17%
Follow NVCT
Alert me
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.00 | 2.41 | 3.30 | 2.75 | 2.09 | 2.38 |
Net Debt/EBITDA |
— | 0.00 | 0.45 | 1.04 | 0.84 | 0.93 | 1.15 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.00 | 0.74 | 0.71 | 0.72 | 0.64 | 0.55 |
| — | 0.18% | 233.98% | (1,188.73%) | (168.51%) | (173.41%) | (205.30%) | |
| — | 0.00% | (387.26%) | (141.05%) | (112.45%) | (100.55%) | (114.76%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 100.00% | (377.56%) | (134.22%) | (182.44%) | (195.61%) | (156.80%) |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | 0.00 | (2.23) | (1.07) | (1.03) | (0.72) | (0.73) |
Cash per Share |
— | 0.00 | 1.35 | 1.58 | 1.23 | 1.08 | 1.45 |
Shareholders Equity per Share |
— | 0.00 | (2.58) | 1.12 | 0.78 | 0.57 | 0.84 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (2.58) | 1.12 | 0.78 | 0.57 | 0.84 |
Free Cash Flow |
— | — | (9.50) | (13.56) | (15.95) | (12.25) | (16.01) |
Working Capital |
— | (0.01) | 3.41 | 14.22 | 12.20 | 9.71 | 18.41 |
Net Current Asset Value |
— | (0.01) | (11.83) | 14.22 | 12.20 | 9.71 | 18.41 |
| Other line items | |||||||
Quick Ratio |
— | 0.00 | 2.37 | 3.23 | 2.74 | 2.08 | 2.38 |
Cash ROIC |
— | 0.00% | 180.48% | (39.63%) | (50.93%) | (43.36%) | (31.99%) |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | 0.00 | (2.23) | (1.07) | (1.03) | (0.72) | (0.73) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | — | 0.53 | 1.98 | 2.84 | 2.63 | 4.39 |
Average Assets |
— | 0.00 | 3.33 | 13.53 | 19.80 | 18.90 | 25.16 |
Average Common Equity |
— | (5.51) | (5.51) | 1.61 | 13.21 | 10.96 | 14.06 |
Columns are period end dates · fundamentals updated 6 Nov 2026